Becton, Dickinson and Company (NYSE:BDX) Board of Directors Authorizes Share Repurchase Plan

Becton, Dickinson and Company (NYSE:BDX) announced that its board has initiated a share buyback plan on Thursday, November 5th, RTT News reports. The company plans to repurchase 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $190.00 to $225.00 and gave the stock a “sector perform” rating in a research note on Friday. Barclays assumed coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and issued a $242.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday. Bank of America lifted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Finally, Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $193.67.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $212.27 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market capitalization of $58.49 billion, a price-to-earnings ratio of 51.27, a PEG ratio of 14.28 and a beta of 0.22. The company’s 50 day simple moving average is $188.17 and its 200 day simple moving average is $170.28. Becton, Dickinson and Company has a 1 year low of $137.35 and a 1 year high of $214.88.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.96 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 13.27 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be issued a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s payout ratio is 126.51%.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,907 shares of company stock valued at $1,269,128 over the last quarter. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.